Strategist-Frontline is set to begin, as the company reports first-line velzatinib data at ASCO.
ApexOnco Front Page
Recent articles
First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
What could be the four HengRui assets picked up by Bristol?
GDC-1261 and INR731 enter phase 1, but how do they act?
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
The company now needs to carry out separate phase 2s of its G12D inhibitor VS-7375.
The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
